

Drug Monograph

Drug/Drug **Adasuve™ (loxapine) aerosol powder / typical**
 Class: **antipsychotic**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each single-use inhaler of Adasuve™ contains 10 mg of loxapine per inhalation.

Manufacturer: Manufactured by: Alexza Pharmaceuticals, Inc., Mountain View, CA 94043
 Manufactured for: Teva Select Brands, Horsham, PA 19044, Division of Teva Pharmaceuticals USA, Inc.

Indications: Adasuve™ is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Costs: \$145.00 per inhaler of Adasuve™ WholesaleAcquisitionCost

Summary of Findings: The Division recommends adding this drug to the existing Atypical Antipsychotic Clinical Edit.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit Clinical Edit

Type of PA Criteria: Increased Risk of ADE Non-Preferred Agent
 Appropriate Indications No PA Required

Prepared By: Katie Wilbers, PharmD
 Date: May 13, 2014